EIB support to the life science sector

World's **largest International Financial Institution**

1958

Established to support long-term investments primarily in the European Union. We have over **60 years' experience** in financing sustainable projects.

Shareholders

Owned by the **Member States** of the European Union.

Source of funds

We raise long-term funds on the international **capital markets** and as a non-profit organisation we pass on **favourable borrowing conditions** to our counterparts.

AAA-rated

We're triple-A rated by all major rating agencies.

2013	2014	2016
Pilot under RSFF	Launched under InnovFin	Expanded under the Junker Plan
100+	**EUR 2.5+ bn**	**EU countries**
Companies to date	Signatures to date	Plus other non-EU

Venture Debt is a debt financing instrument with equity features targeting innovation-driven SMEs and midcaps.



EIB venture debt - directly targeting life science R&D activities

Since the start of the COVID-19 crisis, EIB Group COVID-19 has implemented a series of urgent support steps addressing the economic and liquidity consequences. In addition, in the fight against the disease, the EIB is fully making use of the **venture debt instrument** (under InnovFin or EFSI) to provide **direct and targeted support** to early stage innovative life science companies.

This support directly targets the race in vaccine development, therapeutics and diagnostic solutions against COVID-19.

Infectious Diseases Finance Facility (IDFF) under InnovFin

A venture debt programme established in 2015 under InnovFin targeting early or growth stage life science companies with a **focus on infectious diseases** related activities. Due to the perceived less commercially driven targets, most companies in the infectious diseases field face significant challenges in raising adequate funding for their clinical trials or medical device development.

Currently **17 companies have benefited from the facility for a total volume of c.EUR 400m**, active in vaccines, diagnostics and cures against various infectious diseases.

European Growth Finance Facility (EGFF) under EFSI

The venture debt initiative piloted as GFI under RSFF in 2013, launched as MGF under InnovFin in 2014 and expanded as EGFF under EFSI in 2016. This initiative targets the early and growth stage **highly innovative European companies** in sectors such as ICT, energy efficiency, engineering, but also with a **strong focus on life science**.

As of today, **44 highly innovative biotech or medtech projects (42 companies) have benefited from the facility for a total of over EUR 1.2bn**. These companies are at the forefront of vaccine, diagnostics and treatment development in fields such as immuno-oncology, cardio-vascular diseases, microbiome, orphan diseases, etc.

This **unparalleled activity** has equipped the EIB with a strong expertise in dealing with equity-risk investments in the life science sector and has put the Bank at the forefront of the fight against COVID-19, in partnership with European biotech and medtech companies, but also global players such as EC, WHO, CEPI, GAVI, BGMF, Wellcome Trust, etc.



EIB venture debt - **pre-COVID-19 transactions** (prior to 2020) overview in the life science sector

European Commission

Since the inception of the instrument, the EIB has become the biggest venture debt provider in Europe in the life science sector with a portfolio of **EUR 1.6 bn supporting c.60 innovative medtech and biotech companies**. The pre-COVID-19 portfolio includes **15 companies currently engaged in fighting the disease**.

Biotech

Innocoll

Jennewein Biotechnologie GmbH

valneva
FR, Vaccine, EUR 25m

AMRYT PHARMA

Biofrontera

enterome bioscience

amoéba

olmix

evotec
DE, Cure, EUR 75m

APEIRON BIOLOGICS
AT, Cure, EUR 25m

DEVENISH Beyond Nutrition

Newron

NURITAS
IE, Cure, EUR 30m

PAION

Jennewein Biotechnologie GmbH

advicenne

marino med
AT, Cure, EUR 15m

MOLMED

mabion

BIONTECH
DE, Vaccine, EUR 50m

IDFF

transgene

DaVolterra

AntibioTx – Eliminating resistance to help patients

BiondVax Pharmaceuticals Ltd.

F2G

ISA Pharmaceuticals

AM-PHARMA
NL, Cure, EUR 24m

controlMalaria EU Malaria Fund

Years

2015

2016

2017

2018

2019

Med

CADIVI

MOBIDIAG
FI, Diagnostics, EUR 15m

STAT-Diagnostica

BIOCARTIS
BE, Diagnostics, EUR 24m

UNIVERCELLS
BE, Vaccine, EUR 20m

biosurfit
PT, Diagnostics, EUR 17m

NEW ICON

curetis
DE, Diagnostics, EUR 25m

AMW

medneo

magforce THE NANOMEDICINE COMPANY

cellnovo

MedinCell
FR, Cure, EUR 20m

indivumed
DE, Cure, EUR 40m

Nightingale

NANOBIOTIX

CARMAT

median The Imaging Phenomics Company

Mauna Kea Technologies

itm PASSION FOR PRECISION

Viva sure

MOBIDIAG
FI, Diagnostics, EUR 25m

EIB venture debt – **2020 onwards signatures** and **pipeline transactions** overview in the life science sector

European Commission

Since the beginning of the COVID-19 crisis, the EIB life science team has focused its efforts on supporting biotech and medtech companies in vaccines, treatment and diagnostics against COVID-19 across Europe. In 2020, **6 operations** have already been inked for a total amount of **EUR 280m** against COVID-19. In addition **6 others projects** against COVID-19 are in the pipeline.

Biotech

IDFF

Med

Q2 2020

Q3 2020

Q4 2020 onwards

Pluristem – DE/IL, Cure, EUR 50m

BIONTECH – DE, Vaccine, EUR 100m

CUREVAC – DE, Vaccine, EUR 75m

SANIFIT – SP, EUR 20m

EryDel (Innovation into blood) – IT, EUR 30m

EVAXION – DK, EUR 20m

Scope Fluidics – PL, Diagnostics, EUR 10m

MMI – IT, EUR 30m

oncopeptides – SW, EUR 40m

minoryx therapeutics – SP, EUR 25m

Immunic Therapeutics – DE, Cure, EUR 24.5m

Atriva Therapeutics – DE, Cure, EUR 24m

Pipeline

Vaccine, EUR 25m

EUR 30m

Cure, EUR 15m

Vaccine, EUR 30m

Vaccine, EUR 15m

Vaccine, EUR 15m

Vaccine, EUR 50m

EUR 24.5m

EUR 24m

EUR 15m

+ partnerships with key institutions to fight COVID-19

Gavi The Vaccine Alliance · wellcome · Bill & Melinda Gates foundation · CEPI

Target companies

Innovative company with growth driven by the value of your own intellectual property, and no access to bank debt

Start-up, SME or mid-cap with **less than 3,000 employees** and growing, including pre-profit companies

Company already **raised Series B/C** venture equity and needs additional financing to accelerate growth

Strong and sustainable **business** model/plan, professional **management** & investors, and established corporate **governance**

Investments to be financed are **located in the EU**

Investment structuring (example)

- Average tickets size: EUR 10m – 20m
- Up-front commitment of full capital amount
- Disbursements in 1-2 tranches
- Milestones linked to business plan
- Long availability

- Capital repayment may be bullet, amortising, or "balloon" type
- Long maturity (avg. 5 years per tranche)
- Each tranche has separate 5-year tenor (pictured below 5-year bullet repayment)
- Remuneration may include warrants, interest, PIK, royalties or other, alone or in combination



Due diligence for a venture debt project

Competitive product / service

Sustainable business model and strategy

…providing solid growth perspectives…

… with the skills and experience to deliver …

Experienced management team

Professional corporate governance

Raised equity in the past

Strong shareholder base

… backed by solid capital structure and shareholders

Advantages for stakeholders



Companies

- Increase runway to next milestone or funding round
- Extend runway to cash positive
- Provide cushion

Founders

- Limited dilution & loss of control
- Extend time between next funding round
- Hands-off approach with no direct involvement

Investors

- Complementary to existing equity investment
- IRR enhancement
- Maintenance of control
- Long-term loans match timing of investment

Investment execution process



Contact details

Yu Zhang
Head of Unit
Life-Science and Biotech
Equity, New Products and Special Transactions Department
Operations Directorate

email: y.zhang@eib.org

European Investment Bank
98-100, boulevard Konrad Adenauer
L-2950 Luxembourg